Rebecca Redman

4.8k total citations · 2 hit papers
97 papers, 3.3k citations indexed

About

Rebecca Redman is a scholar working on Epidemiology, Oncology and Hepatology. According to data from OpenAlex, Rebecca Redman has authored 97 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Epidemiology, 25 papers in Oncology and 20 papers in Hepatology. Recurrent topics in Rebecca Redman's work include Head and Neck Cancer Studies (18 papers), Hepatitis C virus research (18 papers) and Antibiotics Pharmacokinetics and Efficacy (16 papers). Rebecca Redman is often cited by papers focused on Head and Neck Cancer Studies (18 papers), Hepatitis C virus research (18 papers) and Antibiotics Pharmacokinetics and Efficacy (16 papers). Rebecca Redman collaborates with scholars based in United States, Japan and France. Rebecca Redman's co-authors include Marin H. Kollef, Lisa A. Bellm, Jordi Rello, Montserrat Vera‐Llonch, Gerry Oster, Daniel A. Ollendorf, Edward Tam, Koné Kaniga, Gilles Tapolsky and Jason Chesney and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Rebecca Redman

95 papers receiving 3.2k citations

Hit Papers

Epidemiology and Outcomes... 2002 2026 2010 2018 2002 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database
    2002 959 citations Rebecca Redman et al. profile →
  2. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
    2019 258 citations Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Redman United States 26 1.4k 906 690 674 548 97 3.3k
Bernard Maître France 36 655 0.5× 520 0.6× 2.5k 3.6× 86 0.1× 255 0.5× 152 4.9k
Francis Zech Belgium 25 853 0.6× 180 0.2× 493 0.7× 1.2k 1.7× 450 0.8× 84 3.1k
Paul Soler France 43 652 0.5× 175 0.2× 2.7k 4.0× 97 0.1× 567 1.0× 94 4.9k
Muriel Fartoukh France 36 823 0.6× 681 0.8× 2.6k 3.8× 164 0.2× 181 0.3× 157 4.0k
Maarten J. H. Slooff Netherlands 47 1.6k 1.1× 351 0.4× 649 0.9× 3.4k 5.0× 1.1k 2.0× 180 6.5k
Joon Chang South Korea 38 1.5k 1.1× 177 0.2× 2.0k 2.9× 54 0.1× 1.0k 1.9× 268 5.2k
Giuseppe D’Amico Italy 40 836 0.6× 183 0.2× 1.1k 1.5× 1.0k 1.5× 216 0.4× 189 7.1k
O. James Garden United Kingdom 46 698 0.5× 95 0.1× 2.5k 3.7× 1.6k 2.4× 2.4k 4.4× 141 6.7k
Robert H. Hyland United States 41 3.9k 2.8× 177 0.2× 2.2k 3.2× 3.2k 4.8× 176 0.3× 119 7.2k
Helmut Ostermann Germany 36 1.4k 1.0× 477 0.5× 577 0.8× 17 0.0× 822 1.5× 134 4.1k

Countries citing papers authored by Rebecca Redman

Since Specialization
Citations

This map shows the geographic impact of Rebecca Redman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Redman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Redman more than expected).

Fields of papers citing papers by Rebecca Redman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Redman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Redman. The network helps show where Rebecca Redman may publish in the future.

Co-authorship network of co-authors of Rebecca Redman

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Redman. A scholar is included among the top collaborators of Rebecca Redman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Redman. Rebecca Redman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferris, Robert L., Rom S. Leidner, Christine H. Chung, et al.. (2025). Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 13(8). e011633–e011633. 1 indexed citations
2.
Demehri, Shadmehr, et al.. (2020). Human papillomavirus-positivity is associated with EREG down-regulation and promoter hypermethylation in head and neck squamous cell carcinoma. Experimental and Molecular Pathology. 117. 104549–104549. 4 indexed citations
3.
Tamura, Kenji, Junji Tsurutani, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 816–826. 258 indexed citations breakdown →
4.
Sato, Ken, Kazuaki Chayama, Katia Alves, et al.. (2017). Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Advances in Therapy. 34(6). 1449–1465. 9 indexed citations
5.
Amsbaugh, Mark J., Mehran Yusuf, Jeremy Gaskins, et al.. (2017). Neck dissection for unknown cancer of the head and neck in the era of chemoradiation. American Journal of Otolaryngology. 38(5). 588–592. 13 indexed citations
6.
Perez, Cesar A., Mark J. Amsbaugh, Wederson M. Claudino, et al.. (2016). High-Dose Versus Weekly Cisplatin Definitive Chemoradiation Therapy for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 94(4). 895–895. 1 indexed citations
7.
Gopalakrishnan, Sathej, Amit Khatri, Sven Mensing, et al.. (2016). Exposure–Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study. Advances in Therapy. 33(4). 670–683. 3 indexed citations
8.
Asselah, Tarik, Christophe Hézode, Roula Qaqish, et al.. (2016). Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. ˜The œLancet. Gastroenterology & hepatology. 1(1). 25–35. 41 indexed citations
9.
Telang, Sucheta, et al.. (2016). Abstract 557: Taking the sweet out of Th17 cells to potentiate immuno-oncology drugs. Cancer Research. 76(14_Supplement). 557–557. 3 indexed citations
10.
Amsbaugh, Mark J., Cesar A. Perez, Jeremy Gaskins, et al.. (2016). Squamous Cell Cancer of an Unknown Primary Head and Neck Site: Is Upfront Neck Dissection Still Relevant in the Era of Chemoradiation?. International Journal of Radiation Oncology*Biology*Physics. 94(4). 894–894. 2 indexed citations
11.
Amsbaugh, Mark J., Mehran Yusuf, Elizabeth Cash, et al.. (2016). Distribution of Cervical Lymph Node Metastases From Squamous Cell Carcinoma of the Oropharynx in the Era of Risk Stratification Using Human Papillomavirus and Smoking Status. International Journal of Radiation Oncology*Biology*Physics. 96(2). 349–353. 30 indexed citations
12.
Hassanein, Tarek, Tarik Asselah, Christophe Hézode, et al.. (2016). Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I). Journal of Hepatology. 64(2). S826–S826. 1 indexed citations
13.
Cannavino, Christopher, Rebecca Redman, Oscar Go, et al.. (2015). Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia. The Pediatric Infectious Disease Journal. 34(11). 1264–1267. 8 indexed citations
14.
15.
Lawitz, Eric, Mihály Makara, Ulus Salih Akarca, et al.. (2015). Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology. 149(4). 971–980.e1. 68 indexed citations
16.
Vaccaro, Nicole, et al.. (2011). Influence of Continuous Venovenous Hemofiltration and Continuous Venovenous Hemodiafiltration on the Disposition of Doripenem. Antimicrobial Agents and Chemotherapy. 55(3). 1187–1193. 16 indexed citations
17.
Vaccaro, Nicole, et al.. (2011). Pharmacokinetics of Single‐Dose Doripenem in Adults With Cystic Fibrosis. The Journal of Clinical Pharmacology. 52(11). 1645–1653. 5 indexed citations
18.
Redman, Rebecca & Thomas M. File. (2009). Safety of Intravenous Infusion of Doripenem. Clinical Infectious Diseases. 49(s1). S28–S35. 18 indexed citations
19.
20.
Trotti, Andy, Adam S. Garden, Padraig Warde, et al.. (2004). A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology*Biology*Physics. 58(3). 674–681. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernard Maître Breakdown of academic impact, for papers by Francis Zech Breakdown of academic impact, for papers by Paul Soler Breakdown of academic impact, for papers by Muriel Fartoukh Breakdown of academic impact, for papers by Maarten J. H. Slooff Breakdown of academic impact, for papers by Joon Chang Breakdown of academic impact, for papers by Giuseppe D’Amico Breakdown of academic impact, for papers by O. James Garden Breakdown of academic impact, for papers by Robert H. Hyland Breakdown of academic impact, for papers by Helmut Ostermann
Rankless by CCL
2026